Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (1): 63-68.DOI: 10.3969/j.issn.1673-8640.2026.01.011
Previous Articles Next Articles
HU Mingxi, GONG Qian, LI Mu, PENG Rong(
)
Received:2024-09-14
Revised:2025-07-27
Online:2026-01-30
Published:2026-01-30
Contact:
PENG Rong
CLC Number:
HU Mingxi, GONG Qian, LI Mu, PENG Rong. Role of PCT,DD,Lac and Alb combined with clinical scores in progression assessment of sepsis[J]. Laboratory Medicine, 2026, 41(1): 63-68.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.01.011
| 组别 | 例数 | PCT/ (ng·mL-1) | DD/ (mg·L-1) | Lac/ (mmol·L-1) | Alb/ (g·L-1) | SOFA评分/ 分 | APACHEⅡ 评分/分 |
|---|---|---|---|---|---|---|---|
| 脓毒症组 | 113 | 5.54(3.10~23.70) | 4.65(2.00~8.00) | 1.80(1.40~2.70) | 29.48±5.27 | 6.92±2.13 | 21.81±2.24 |
| 脓毒性休克组 | 87 | 15.29(4.70~41.70) | 6.23(4.00~9.50) | 2.50(1.90~3.70) | 27.80±6.09 | 7.19±1.89 | 22.74±2.66 |
| 统计值 | -2.741 | -2.951 | -4.613 | 2.088 | -2.077 | -2.624 | |
| P值 | 0.006 | 0.003 | <0.001 | 0.038 | 0.041 | 0.008 |
| 组别 | 例数 | PCT/ (ng·mL-1) | DD/ (mg·L-1) | Lac/ (mmol·L-1) | Alb/ (g·L-1) | SOFA评分/ 分 | APACHEⅡ 评分/分 |
|---|---|---|---|---|---|---|---|
| 脓毒症组 | 113 | 5.54(3.10~23.70) | 4.65(2.00~8.00) | 1.80(1.40~2.70) | 29.48±5.27 | 6.92±2.13 | 21.81±2.24 |
| 脓毒性休克组 | 87 | 15.29(4.70~41.70) | 6.23(4.00~9.50) | 2.50(1.90~3.70) | 27.80±6.09 | 7.19±1.89 | 22.74±2.66 |
| 统计值 | -2.741 | -2.951 | -4.613 | 2.088 | -2.077 | -2.624 | |
| P值 | 0.006 | 0.003 | <0.001 | 0.038 | 0.041 | 0.008 |
| 组别 | 例数 | DD/(mg·L-1) | Lac/(mmol·L-1) | Alb/(g·L-1) | SOFA评分/分 | APACHEⅡ评分/分 |
|---|---|---|---|---|---|---|
| PCT 2~10 ng·mL-1组 | 95 | 4.22(2.00~8.10) | 1.80(1.40~2.30) | 31.85±6.07 | 6.83±1.67 | 22.18±1.73 |
| PCT 10~30 ng·mL-1组 | 51 | 7.72(3.80~11.60)* | 2.20(1.60~2.90)* | 30.50±5.54* | 6.91±1.88* | 22.20±3.36* |
| PCT 30~100 ng·mL-1组 | 32 | 4.83(3.00~7.20)*# | 2.50(1.80~3.80)*# | 30.20±6.08*# | 7.58±2.67*# | 21.98±2.50*# |
| PCT>100 ng·mL-1组 | 22 | 4.97(3.00~7.20)*#∆ | 2.75(1.60~4.40)*#∆ | 27.65±6.35*#∆ | 8.25±1.28*#∆ | 24.00±4.00*#∆ |
| 统计值 | 15.603 0 | 19.713 0 | 3.162 0 | 2.735 7 | 1.553 6 | |
| P值 | <0.001 | <0.001 | 0.026 0 | 0.048 0 | 0.202 0 |
| 组别 | 例数 | DD/(mg·L-1) | Lac/(mmol·L-1) | Alb/(g·L-1) | SOFA评分/分 | APACHEⅡ评分/分 |
|---|---|---|---|---|---|---|
| PCT 2~10 ng·mL-1组 | 95 | 4.22(2.00~8.10) | 1.80(1.40~2.30) | 31.85±6.07 | 6.83±1.67 | 22.18±1.73 |
| PCT 10~30 ng·mL-1组 | 51 | 7.72(3.80~11.60)* | 2.20(1.60~2.90)* | 30.50±5.54* | 6.91±1.88* | 22.20±3.36* |
| PCT 30~100 ng·mL-1组 | 32 | 4.83(3.00~7.20)*# | 2.50(1.80~3.80)*# | 30.20±6.08*# | 7.58±2.67*# | 21.98±2.50*# |
| PCT>100 ng·mL-1组 | 22 | 4.97(3.00~7.20)*#∆ | 2.75(1.60~4.40)*#∆ | 27.65±6.35*#∆ | 8.25±1.28*#∆ | 24.00±4.00*#∆ |
| 统计值 | 15.603 0 | 19.713 0 | 3.162 0 | 2.735 7 | 1.553 6 | |
| P值 | <0.001 | <0.001 | 0.026 0 | 0.048 0 | 0.202 0 |
| 项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
|---|---|---|---|---|---|
| PCT | 0.003 | 0.007 | 0.209 | 0.648 | 1.003(0.989~1.018) |
| DD | 0.005 | 0.023 | 0.046 | 0.830 | 1.005(0.956~1.052) |
| Lac | 0.153 | 0.088 | 3.266 | 0.040 | 1.166(0.988~1.419) |
| Alb | -0.041 | 0.033 | 1.511 | 0.219 | 0.960(0.897~1.024) |
| SOFA评分 | 0.838 | 0.164 | 47.544 | 0.046 | 2.311(1.708~3.333) |
| APACHEⅡ评分 | 0.236 | 0.108 | 4.221 | 0.040 | 1.266(1.010~1.601) |
| 项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
|---|---|---|---|---|---|
| PCT | 0.003 | 0.007 | 0.209 | 0.648 | 1.003(0.989~1.018) |
| DD | 0.005 | 0.023 | 0.046 | 0.830 | 1.005(0.956~1.052) |
| Lac | 0.153 | 0.088 | 3.266 | 0.040 | 1.166(0.988~1.419) |
| Alb | -0.041 | 0.033 | 1.511 | 0.219 | 0.960(0.897~1.024) |
| SOFA评分 | 0.838 | 0.164 | 47.544 | 0.046 | 2.311(1.708~3.333) |
| APACHEⅡ评分 | 0.236 | 0.108 | 4.221 | 0.040 | 1.266(1.010~1.601) |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| PCT | 0.613(0.535~0.691) | 4.46 ng·mL-1 | 78.2 | 46.0 | 0.242 |
| DD | 0.622(0.545~0.698) | 2.79 mg·L-1 | 90.8 | 34.5 | 0.253 |
| Lac | 0.690(0.618~0.763) | 2.07 mmol·L-1 | 70.1 | 59.3 | 0.294 |
| Alb | 0.572(0.492~0.652) | 27.6 g·L-1 | 66.4 | 47.1 | 0.135 |
| APACHEⅡ评分 | 0.791(0.720~0.861) | 22.5分 | 88.5 | 79.6 | 0.646 |
| SOFA评分 | 0.809(0.740~0.870) | 7.5分 | 64.4 | 95.6 | 0.599 |
| 联合检测 | 0.867(0.811~0.922) | 0.40 | 82.8 | 85.0 | 0.677 |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性% | 特异性/% | 约登指数 |
|---|---|---|---|---|---|
| PCT | 0.613(0.535~0.691) | 4.46 ng·mL-1 | 78.2 | 46.0 | 0.242 |
| DD | 0.622(0.545~0.698) | 2.79 mg·L-1 | 90.8 | 34.5 | 0.253 |
| Lac | 0.690(0.618~0.763) | 2.07 mmol·L-1 | 70.1 | 59.3 | 0.294 |
| Alb | 0.572(0.492~0.652) | 27.6 g·L-1 | 66.4 | 47.1 | 0.135 |
| APACHEⅡ评分 | 0.791(0.720~0.861) | 22.5分 | 88.5 | 79.6 | 0.646 |
| SOFA评分 | 0.809(0.740~0.870) | 7.5分 | 64.4 | 95.6 | 0.599 |
| 联合检测 | 0.867(0.811~0.922) | 0.40 | 82.8 | 85.0 | 0.677 |
| [1] | XIA Y, ZOU L, LI D, et al. The ability of an improved qSOFA score to predict acute sepsis severity and prognosis among adult patients[J]. Medicine(Baltimore), 2020, 99(5):e18942. |
| [2] |
SHIME N, NAKADA T A, YATABE T, et al. The Japanese clinical practice guidelines for management of sepsis and septic shock 2024[J]. J Intensive Care, 2025, 13(1):15.
DOI PMID |
| [3] |
HAMADE B, HUANG D T. Procalcitonin:where are we now?[J]. Crit Care Clin, 2020, 36(1):23-40.
DOI URL |
| [4] | 牟青松, 任香凝, 陆金帅, 等. 成人脓毒症休克患者院内死亡风险的早期预测及简易评分表构建[J]. 重庆医学, 2024, 53(5):682-689. |
| [5] | 闫冬梅, 汪辉. 血栓弹力图参数联合INR DD水平对脓毒症伴DIC早期诊断的价值分析[J]. 河北医学, 2023, 29(11):1896-1902. |
| [6] | MA H, LIU H, WU C, et al. Diagnostic value of serum heparin binding protein,blood lactic acid combined with hs-CRP in sepsis and its relationship with prognosis[J]. Evid Based Complement Alternat Med, 2021, 2021:5023733. |
| [7] |
HU J, LV C, HU X, et al. Effect of hypoproteinemia on the mortality of sepsis patients in the ICU:a retrospective cohort study[J]. Sci Rep, 2021, 11(1):24379.
DOI |
| [8] | 中国医师协会急诊医师分会, 中国研究型医院学会休克与脓毒症专业委员会. 中国脓毒症/脓毒性休克急诊治疗指南(2018)[J]. 感染、炎症、修复, 2019, 20(1):3-22. |
| [9] |
DOLMATOVA E V, WANG K, MANDAVILLI R, et al. The effects of sepsis on endothelium and clinical implications[J]. Cardiovasc Res, 2021, 117(1):60-73.
DOI PMID |
| [10] |
AGARWAL R, SHARMA K, MEHNDIRATTA M, et al. Role of repeat procalcitonin estimation at 48 hours for outcome in pregnancy associated sepsis:a prospective observational study[J]. Obstet Gynecol Sci, 2021, 64(1):27-33.
DOI URL |
| [11] | 王亚敏, 刘建敏, 兰浩云. 血清降钙素原D-二聚体视黄醇结合蛋白与脓毒症患者病情程度及预后关系研究[J]. 实用医技杂志, 2024, 31(10):722-726. |
| [12] | 宁敏彤. 血浆白蛋白、降钙素原、C-反应蛋白的动态变化对脓毒性休克患者预后的评估[D]. 太原: 山西医科大学, 2024. |
| [13] |
潘锡龙, 徐志远, 谢锋, 等. 不同脓毒症诊断标准中降钙素原的临床意义[J]. 检验医学, 2021, 36(12):1215-1218.
DOI |
| [14] |
OSAMURA Y, NISHIYAMA H, HATTORI T, et al. Clinico-bacterial and prognostic factors in patients with suspected blood stream infection and elevated serum procalcitonin levels[J]. Nagoya J Med Sci, 2022, 84(2):230-246.
DOI PMID |
| [15] | 赵梦雅, 段美丽. 血乳酸和乳酸清除率与降钙素原联合检测对脓毒症患者病情严重程度及预后评估的临床意义[J]. 中华危重病急救医学, 2020, 32(4):449-453. |
| [16] |
IBA T, CONNORS J M, NAGAOKA I, et al. Recent advances in the research and management of sepsis-associated DIC[J]. Int J Hematol, 2021, 113(1):24-33.
DOI PMID |
| [17] | LUNGU N, POPESCU D E, GORUN F I, et al. D-dimer as a useful biomarker in early diagnosis of neonatal sepsis:a single-center study from Romania[J]. Cureus, 2024, 16(7):e65213. |
| [18] | 吴姗姗. D-二聚体对于重症监护内脓毒症和非脓毒症患者预后的评估价值:一项基于MIMIC-Ⅲ数据库的回顾性研究[C]. 沈阳: 第二十届沈阳科学学术年会论文集, 2023. |
| [19] | 韩永燕, 杨俊礼, 孟会敏, 等. D-二聚体与白蛋白比值联合乳酸评价EICU脓毒症患者近期预后的研究[J]. 临床急诊杂志, 2025, 26(1):49-54. |
| [20] | 梁旭, 李国旗, 张红玉, 等. 血乳酸、IL-6联合SOFA评分对脓毒症患者28 d死亡风险的预测价值[J]. 暨南大学学报(自然科学与医学版), 2024, 45(1):43-50. |
| [21] | EVANS L, RHODES A, ALHAZZANI W, et al. Surviving sepsis campaign:international guidelines for management of sepsis and septic shock 2021[J]. Crit Care Med, 2021, 49(11):e1063-e1143. |
| [22] |
SUN Z, SONG Y, LI J, et al. Potential biomarker for diagnosis and therapy of sepsis:lactylation[J]. Immun Inflamm Dis, 2023, 11(10):e1042.
DOI URL |
| [23] | 刘志勇, 蒋建强, 毛萍萍, 等. 外周灌注指数和氧负荷试验对脓毒症休克患者复苏后死亡率的预测作用[J]. 医药论坛杂志, 2021, 42(23):39-43. |
| [24] | 曹晓梅, 姚杨, 彭伊梦, 等. 乳酸与乳酸清除率在脓毒症预后中的研究进展[J]. 医学信息, 2023, 36(17):180-183. |
| [25] | POMPILI E, ZACCHERINI G, BALDASSARRE M, et al. Albumin administration in internal medicine:a journey between effectiveness and futility[J]. Eur J Intern Med, 2023,117:28-37. |
| [26] | 查佳安. 清蛋白水平联合INR在脓毒症患者死亡预测的应用研究[J]. 现代医药卫生, 2021, 37(13):2250-2253. |
| [27] |
WIEDERMANN C J. Controversies surrounding albumin use in sepsis:lessons from cirrhosis[J]. Int J Mol Sci, 2023, 24(24):17606.
DOI URL |
| [28] | YU Y T, LIU J, HU B, et al. Expert consensus on the use of human serum albumin in critically ill patients[J]. Chin Med J(Engl), 2021, 134(14):1639-1654. |
| [29] | 文阳芬. 低白蛋白血症在脓毒症患者病情严重程度方面的价值探讨[D]. 衡阳: 南华大学, 2020. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||